A Comprehensive Review on the Methods Developed for the Determination of Riluzole and Citalopram Hydrobromide

The accurate determination of Riluzole and Citalopram Hydrobromide in bulk synthetic mixtures is of paramount importance in pharmaceutical quality control, drug development, and clinical research. Riluzole, a benzothiazole derivative, is primarily used in the management of amyotrophic lateral sclerosis (ALS), while Citalopram Hydrobromide, a selective serotonin reuptake inhibitor (SSRI), is widely prescribed for depression and anxiety disorders. Both drugs, despite their distinct therapeutic roles, require precise analytical methods to ensure efficacy, safety, and regulatory compliance. Reverse Phase High-Performance Liquid Chromatography (RP‑HPLC) has emerged as a validated and versatile technique for their simultaneous estimation, offering high sensitivity, reproducibility, and robustness. Previous studies have demonstrated the successful application of RP‑HPLC in quantifying Riluzole, often in combination with other drugs such as Levodopa, with excellent accuracy, precision, and low detection limits. Similarly, validated RP‑HPLC methods for Citalopram Hydrobromide have emphasized stability‑indicating capabilities, impurity profiling, and robustness under stress conditions, ensuring reliable separation of parent drug and degradation products. These findings highlight RP‑HPLC’s adaptability in handling diverse physicochemical properties and complex pharmaceutical matrices. The validation of these methods under International Council for Harmonisation (ICH) guidelines confirms their suitability for routine quality control, stability studies, and impurity analysis. Parameters such as linearity, accuracy, precision, limit of detection (LOD), and limit of quantification (LOQ) consistently meet regulatory standards, reinforcing the reliability of RP‑HPLC in pharmaceutical analysis. Moreover, the comparative evaluation of Riluzole and Citalopram Hydrobromide methods reveals complementary strengths: Riluzole methods emphasize simplicity and sensitivity, while Citalopram methods highlight robustness and stability‑indicating performance. Looking ahead, coupling RP‑HPLC with advanced hyphenated techniques such as LC‑MS/MS offers opportunities for enhanced sensitivity, structural elucidation, and bioanalytical applications. This integration could expand the scope of Riluzole and Citalopram analysis into pharmacokinetics, metabolite profiling, and clinical monitoring. Additionally, the adoption of green chromatography principles and automation will further improve sustainability, efficiency, and throughput in routine pharmaceutical laboratories. In conclusion, validated RP‑HPLC methods for Riluzole and Citalopram Hydrobromide exemplify the critical role of chromatographic techniques in modern pharmaceutical sciences. Their proven accuracy, reproducibility, and regulatory compliance make them indispensable tools for ensuring drug quality, patient safety, and advancing therapeutic research.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-13
DOI
https://doi.org/10.5281/zenodo.24185609
Primary Topic
Analytical Methods in Pharmaceuticals
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Comprehensive Review on the Methods Developed for the Determination of Riluzole and Citalopram Hydrobromide

Purvi Ramanuj, Dr. Pragnesh Patani, Patel Vishwa Shaileshbhai
3 links
Zenodo (CERN European Organization for Nuclear Research)
Analytical Methods in Pharmaceuticals
article

A Comprehensive Review on the Methods Developed for the Determination of Riluzole and Citalopram Hydrobromide

Purvi Ramanuj, Dr. Pragnesh Patani, Patel Vishwa Shaileshbhai
article en

Abstract

The accurate determination of Riluzole and Citalopram Hydrobromide in bulk synthetic mixtures is of paramount importance in pharmaceutical quality control, drug development, and clinical research. Riluzole, a benzothiazole derivative, is primarily used in the management of amyotrophic lateral sclerosis (ALS), while Citalopram Hydrobromide, a selective serotonin reuptake inhibitor (SSRI), is widely prescribed for depression and anxiety disorders. Both drugs, despite their distinct therapeutic roles, require precise analytical methods to ensure efficacy, safety, and regulatory compliance. Reverse Phase High-Performance Liquid Chromatography (RP‑HPLC) has emerged as a validated and versatile technique for their simultaneous estimation, offering high sensitivity, reproducibility, and robustness. Previous studies have demonstrated the successful application of RP‑HPLC in quantifying Riluzole, often in combination with other drugs such as Levodopa, with excellent accuracy, precision, and low detection limits. Similarly, validated RP‑HPLC methods for Citalopram Hydrobromide have emphasized stability‑indicating capabilities, impurity profiling, and robustness under stress conditions, ensuring reliable separation of parent drug and degradation products. These findings highlight RP‑HPLC’s adaptability in handling diverse physicochemical properties and complex pharmaceutical matrices. The validation of these methods under International Council for Harmonisation (ICH) guidelines confirms their suitability for routine quality control, stability studies, and impurity analysis. Parameters such as linearity, accuracy, precision, limit of detection (LOD), and limit of quantification (LOQ) consistently meet regulatory standards, reinforcing the reliability of RP‑HPLC in pharmaceutical analysis. Moreover, the comparative evaluation of Riluzole and Citalopram Hydrobromide methods reveals complementary strengths: Riluzole methods emphasize simplicity and sensitivity, while Citalopram methods highlight robustness and stability‑indicating performance. Looking ahead, coupling RP‑HPLC with advanced hyphenated techniques such as LC‑MS/MS offers opportunities for enhanced sensitivity, structural elucidation, and bioanalytical applications. This integration could expand the scope of Riluzole and Citalopram analysis into pharmacokinetics, metabolite profiling, and clinical monitoring. Additionally, the adoption of green chromatography principles and automation will further improve sustainability, efficiency, and throughput in routine pharmaceutical laboratories. In conclusion, validated RP‑HPLC methods for Riluzole and Citalopram Hydrobromide exemplify the critical role of chromatographic techniques in modern pharmaceutical sciences. Their proven accuracy, reproducibility, and regulatory compliance make them indispensable tools for ensuring drug quality, patient safety, and advancing therapeutic research.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Analytical Methods in Pharmaceuticals
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon